FDA ‘very comfortable’ with vaccine safety profile for 16, 17 year olds
Common questions surrounding the newly authorized Pfizer vaccine include safety for teenagers and the risk of allergic reactions.
Though the final data doesn’t have conclusive data on 16 and 17 year olds because they weren’t enrolled in trials until more recently, the FDA is “very comfortable with the safety profile that was observed in 17 and 16 year olds," Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, told reporters.
Regarding allergies, Marks said 1.6% of the population has had a severe allergic reaction.
Marks said you should notify your doctor if you’ve ever had an allergic reaction to a vaccine and noted that sites that administer the vaccine will have medications on hand to respond to an allergic reaction.
ABC News’ Anne Flaherty contributed to this report.